The FDA announced a pilot program Monday that could shave six to 12 months off early-stage clinical trial timelines, part of a concerted push by the Trump administration to stop the United States from bleeding clinical research to China. The pilot, detailed by federal health officials on a Monday morning call, accompanies a proposed permanent overhaul of the Investigational New Drug pathway in the president's 2027 fiscal budget — a change championed by former FDA...